Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, ...

Millions of Americans who could benefit from GLP-1 weight-loss drugs are caught in the middle of a battle between drug ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Elevance Health Inc. was hit with a proposed class action by a woman who says the insurer wrongly refuses to cover the weight-loss drug Zepbound for patients who need it to treat obstructive sleep ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, German ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...